Abstract

Manifestations of mantle cell lymphoma were recognized in the 1970s as distinct from those associated with the more readily classifiable lymphomas. It was not until the 1990s, however, that observation of a combination of immunologic, cytogenetic, and molecular genetic abnormalities characteristic of this new malignancy confirmed its existence. The clinical and pathologic entity was named mantle cell lymphoma and in 1994 was incorporated into the Revised European American Lymphoma Classification. Mantle cell lymphoma is a CD5 positive, B-cell lymphoma that usually displays the t(11;14). The lymphoma has a striking male predominance and is widely disseminated at diagnosis in 80% of patients. Mantle cell lymphoma responds poorly to available therapies, and the median survival in approximately 3 years.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalONCOLOGY
Volume12
Issue number10 SUPPL. 8
StatePublished - Dec 5 1998

Fingerprint

Mantle-Cell Lymphoma
Lymphoma
B-Cell Lymphoma
Cytogenetics
Molecular Biology
Observation
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Management of mantle cell lymphoma. / Armitage, James Olen.

In: ONCOLOGY, Vol. 12, No. 10 SUPPL. 8, 05.12.1998, p. 49-55.

Research output: Contribution to journalReview article

Armitage, JO 1998, 'Management of mantle cell lymphoma', ONCOLOGY, vol. 12, no. 10 SUPPL. 8, pp. 49-55.
Armitage JO. Management of mantle cell lymphoma. ONCOLOGY. 1998 Dec 5;12(10 SUPPL. 8):49-55.
Armitage, James Olen. / Management of mantle cell lymphoma. In: ONCOLOGY. 1998 ; Vol. 12, No. 10 SUPPL. 8. pp. 49-55.
@article{ce6ea62d32794c26a69d410b1b64f1f8,
title = "Management of mantle cell lymphoma",
abstract = "Manifestations of mantle cell lymphoma were recognized in the 1970s as distinct from those associated with the more readily classifiable lymphomas. It was not until the 1990s, however, that observation of a combination of immunologic, cytogenetic, and molecular genetic abnormalities characteristic of this new malignancy confirmed its existence. The clinical and pathologic entity was named mantle cell lymphoma and in 1994 was incorporated into the Revised European American Lymphoma Classification. Mantle cell lymphoma is a CD5 positive, B-cell lymphoma that usually displays the t(11;14). The lymphoma has a striking male predominance and is widely disseminated at diagnosis in 80{\%} of patients. Mantle cell lymphoma responds poorly to available therapies, and the median survival in approximately 3 years.",
author = "Armitage, {James Olen}",
year = "1998",
month = "12",
day = "5",
language = "English (US)",
volume = "12",
pages = "49--55",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 8",

}

TY - JOUR

T1 - Management of mantle cell lymphoma

AU - Armitage, James Olen

PY - 1998/12/5

Y1 - 1998/12/5

N2 - Manifestations of mantle cell lymphoma were recognized in the 1970s as distinct from those associated with the more readily classifiable lymphomas. It was not until the 1990s, however, that observation of a combination of immunologic, cytogenetic, and molecular genetic abnormalities characteristic of this new malignancy confirmed its existence. The clinical and pathologic entity was named mantle cell lymphoma and in 1994 was incorporated into the Revised European American Lymphoma Classification. Mantle cell lymphoma is a CD5 positive, B-cell lymphoma that usually displays the t(11;14). The lymphoma has a striking male predominance and is widely disseminated at diagnosis in 80% of patients. Mantle cell lymphoma responds poorly to available therapies, and the median survival in approximately 3 years.

AB - Manifestations of mantle cell lymphoma were recognized in the 1970s as distinct from those associated with the more readily classifiable lymphomas. It was not until the 1990s, however, that observation of a combination of immunologic, cytogenetic, and molecular genetic abnormalities characteristic of this new malignancy confirmed its existence. The clinical and pathologic entity was named mantle cell lymphoma and in 1994 was incorporated into the Revised European American Lymphoma Classification. Mantle cell lymphoma is a CD5 positive, B-cell lymphoma that usually displays the t(11;14). The lymphoma has a striking male predominance and is widely disseminated at diagnosis in 80% of patients. Mantle cell lymphoma responds poorly to available therapies, and the median survival in approximately 3 years.

UR - http://www.scopus.com/inward/record.url?scp=0031788754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031788754&partnerID=8YFLogxK

M3 - Review article

VL - 12

SP - 49

EP - 55

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 8

ER -